Eli Lilly and shows rapid expansion with metabolic health treatments and high revenue growth. Novo Nordisk A/S maintains a strong global footprint with deep expertise in diabetes and obesity care.
| Quartal / Datum | EPS (USD) | Schätzung (USD) | Abweichung |
|---|
| Quartal / Datum | Umsatz (Mrd USD) | Schätzung (Mrd USD) | Abweichung |
|---|